# Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

> **NCT05200260** · PHASE2 · RECRUITING · sponsor: **Shanghai Gynecologic Oncology Group** · enrollment: 220 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **PROCEDURE:** Primary debulking surgery
- **PROCEDURE:** Neoadjuvant chemotherapy
- **DRUG:** PARP inhibitor
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05200260
- **Lead sponsor:** Shanghai Gynecologic Oncology Group
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200260, "Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05200260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*